Stay updated on CABozantinib in NSCLC MET Clinical Trial
Sign up to get notified when there's something new on the CABozantinib in NSCLC MET Clinical Trial page.

Latest updates to the CABozantinib in NSCLC MET Clinical Trial page
- Check4 days agoChange DetectedThe web page has been updated to version 2.16.5, indicating a new release. However, the previous information regarding the modernization of ClinicalTrials.gov data ingest has been removed.SummaryDifference1%
- Check12 days agoNo Change Detected
- Check19 days agoChange DetectedThe expected modernization date for the ClinicalTrials.gov data ingest has been updated from June 2025 to July 2025.SummaryDifference1%
- Check26 days agoChange DetectedThe web page has been updated from version 2.16.1 to version 2.16.2.SummaryDifference0.1%
- Check33 days agoNo Change Detected
- Check40 days agoChange DetectedThe web page has been updated to indicate that the ClinicalTrials.gov data ingest will be modernized in June 2025, allowing API users to provide input before implementation. Additionally, the revision number has been updated from v2.15.2 to v2.16.1.SummaryDifference2%
- Check69 days agoChange DetectedThe web page has been updated from version 2.15.0 to version 2.15.2.SummaryDifference0.1%
- Check76 days agoChange DetectedThe page has undergone significant content changes, including the removal of detailed study information regarding a phase II trial for Non-Small Cell Lung Cancer (NSCLC) and the addition of a new version revision. Notably, the principal investigator's name has been retained, but the detailed eligibility criteria and treatment protocols have been deleted.SummaryDifference29%
Stay in the know with updates to CABozantinib in NSCLC MET Clinical Trial
Enter your email address, and we'll notify you when there's something new on the CABozantinib in NSCLC MET Clinical Trial page.